Olaparib (AZD2281): Selective PARP-1/2 Inhibitor for BRCA-Deficient Cancer Research

Executive Summary: Olaparib (AZD2281, Ku-0059436) is a potent inhibitor of poly(ADP-ribose) polymerase-1 and -2 (PARP-1/2), with IC₅₀ values of 5 nM and 1 nM respectively, validated in multiple cancer models (Borchert et al., 2019). It selectively induces cytotoxicity in BRCA-deficient and homologous recombination-deficient (HRD) cells via synthetic lethality. The compound enhances DNA damage and radiosensitization, especially in non-small cell lung carcinoma (NSCLC) xenografts. Sensitivity to olaparib is modulated by ATM kinase activity, with increased susceptibility in ATM-deficient cells. APExBIO provides Olaparib (A4154) as a validated research tool for DNA damage response and BRCA-associated cancer studies (APExBIO product page).

Biological Rationale

DNA double-strand breaks (DSBs) are critical lesions that threaten genome integrity. Homologous recombination repair (HRR) is the primary mechanism for accurate DSB repair. Defects in HRR, termed 'BRCAness', are common in several malignancies, including malignant pleural mesothelioma (MPM) and BRCA1/2-mutated tumors (Borchert et al., 2019). In HR-deficient cells, reliance on backup repair pathways, such as base excision repair mediated by PARP1/2, increases. Inhibiting PARP in these contexts leads to unrepaired DNA damage and cell death—an effect described as synthetic lethality. Thus, PARP inhibitors like Olaparib target the Achilles' heel of HR-deficient cancers, providing a rationale for selective cytotoxicity. This approach has been extended to tumors with broader homologous recombination deficiencies beyond classic BRCA mutations, including BAP1 loss and ATM deficiency.

Mechanism of Action of Olaparib (AZD2281, Ku-0059436)

Olaparib is a competitive inhibitor of PARP-1 and PARP-2 enzymatic activity. It binds the NAD⁺ binding site of PARP, blocking the enzyme's role in repairing single-strand DNA breaks. Accumulation of unrepaired single-strand breaks leads to replication fork collapse and double-strand break formation during S phase. In HR-deficient cells, these DSBs cannot be repaired efficiently, resulting in apoptosis or senescence. Olaparib has demonstrated high selectivity, with IC₅₀ values of 5 nM (PARP1) and 1 nM (PARP2) in biochemical assays (APExBIO). In vivo, olaparib increases DNA damage markers (e.g., γH2AX) and caspase activation, especially under radiosensitizing conditions. The compound's efficacy is further modulated by ATM kinase status, with ATM-deficient models showing enhanced sensitivity.

Evidence & Benchmarks

• Olaparib induces apoptosis and senescence in BAP1-mutated mesothelioma cell lines at 10 μM for 1 hour in vitro (Borchert et al., 2019).
• In NSCLC xenograft models, olaparib enhances radiosensitivity, increasing DNA damage and improving tumor perfusion at 50 mg/kg/day intraperitoneally for 14 days (Borchert et al., 2019).
• BRCAness phenotype, including BAP1 loss, increases susceptibility to PARP inhibition, with about 10% of clinical mesothelioma samples showing this gene expression pattern (Borchert et al., 2019, Table 1).
• ATM-deficient cell lines display increased olaparib sensitivity, supporting its use in DDR-deficient models (Borchert et al., 2019).
• Olaparib demonstrates poor solubility in ethanol and water but is soluble at ≥21.72 mg/mL in DMSO; stock solutions are stable below -20°C (APExBIO).

Compared with previous analyses, this article provides detailed experimental benchmarks and explicit workflow recommendations for integrating Olaparib into BRCA-deficient and HRD research models.

Applications, Limits & Misconceptions

Olaparib is widely used for:

• DNA damage response assays in BRCA1/2- and BAP1-mutated models.
• Radiosensitization studies in NSCLC and other solid tumor xenografts.
• Targeted therapy research in cancers with homologous recombination deficiency (HRD).
• Modelling platinum resistance and synthetic lethality in vitro and in vivo.

Common Pitfalls or Misconceptions

• Not all DNA repair-deficient tumors are equally sensitive: Tumors lacking HRD or with compensatory repair pathways may show resistance.
• BRCA1/2 wild-type status does not guarantee resistance: 'BRCAness' phenotypes from other gene alterations can confer sensitivity (Borchert et al., 2019).
• Solubility limitations: Olaparib is not soluble in water or ethanol; improper preparation can result in precipitation or loss of potency (APExBIO).
• Long-term solution storage is not recommended: Stock solutions should be freshly prepared and stored below -20°C for optimal stability.
• Off-target effects at high concentrations: Exceeding recommended doses (e.g., >10 μM in cell culture) can compromise selectivity and result in non-specific cytotoxicity.

This article extends the protocol-focused discussion from Solving Laboratory Challenges with Olaparib by emphasizing mechanistic selectivity and critical benchmarks for BRCA-deficient research models.

Workflow Integration & Parameters

For in vitro studies, Olaparib is typically used at 10 μM for 1 hour in cell culture systems. Stock solutions should be prepared in DMSO at concentrations ≥21.72 mg/mL. For in vivo mouse models, the standard regimen is 50 mg/kg/day administered intraperitoneally for 14 consecutive days (Borchert et al., 2019). ATM and BAP1 status should be characterized prior to PARP inhibitor studies to predict response. For DNA damage response assays, co-treatment with platinum agents (e.g., cisplatin) may reveal synergistic effects, especially in HRD contexts.

Researchers should reference the Olaparib (AZD2281, Ku-0059436) product page from APExBIO for validated protocols and product quality specifications. This article updates the mechanistic insights presented in Olaparib (AZD2281): Advanced Strategies in Overcoming Platinum Resistance by incorporating recent benchmarks in ATM-deficient and BAP1-mutated models.

Conclusion & Outlook

Olaparib (AZD2281, Ku-0059436) is a benchmark PARP-1/2 inhibitor for dissecting DNA repair mechanisms and developing targeted therapies in BRCA-deficient and homologous recombination-deficient cancers. Its selectivity and validated efficacy in both in vitro and in vivo models support broad adoption for DNA damage response and radiosensitization studies. Continued integration with precision oncology strategies and expanded biomarker profiling (e.g., ATM, BAP1, HRD signatures) will further optimize its translational utility. APExBIO's A4154 kit provides robust, reproducible access to this compound for advanced cancer research applications.